Editorial

Pararajasegaram, R.

doi:10.1016/s0002-9394(99)00251-2

Cited by 128 publications

(49 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myopia is an important cause of reduced vision in populations throughout the world and is one of the five immediate priorities for the ‘Vision 2020’ initiative by the World Health Organization (WHO) (Pararajasegaram 1998). Approximately 2% of the United States population is myopic at school entry (Blum 1959)and about 15% of the people entering high schools are myopic (Sperduto 1983).…”

Section: Introductionmentioning

confidence: 99%

“…Strategies to control progression of myopia gain importance in the context of the ‘Vision 2020’ initiative by the WHO to eliminate preventable causes of blindness, including risks associated with high myopia, by the year 2020 (Pararajasegaram 1998). Interventions that have been explored for this purpose include bifocal spectacles, cycloplegic drops, intraocular pressure-lowering drugs, muscarinic receptor antagonists and contact lenses.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interventions to slow progression of myopia in children

Walline

Lindsley

Vedula

et al. 2011

Cochrane Database of Systematic Reviews

219

132

View full text Add to dashboard Cite

Istotność kontroli krótkowzroczności jest związana z rosnącym odsetkiem światowej populacji obarczonej tą wadą wzroku, a jest ona jednym z czynników ryzyka wystąpienia innych chorób oczu. W licznych pracach poddawano analizie wpływ różnych metod optycznych i farmakologicznych na spowolnienie progresji krótkowzroczności. Stosowano zarówno korekcję okularową i soczewkami kontaktowymi o konstrukcjach dwu-i wieloogniskowych, jak i ortokeratologię. Wśród leków badano przede wszystkim wpływ różnych stężeń atropiny na zahamowanie progresji krótkowzroczności. Rzadziej opisywano zastosowanie innych leków, np. pirenzepiny. Za najbardziej skuteczne metody, powodujące największe spowolnienie zwiększania się krótkowzroczności, uznano zastosowanie soczewek kontaktowych modyfikujących obwodowe rozogniskowanie, soczewek ortokeratologicznych oraz użycie atropiny, przede wszystkim w niskich stężeniach. W licznych opracowaniach podkreślono też szkodliwy -przyspieszający narastanie krótkowzroczności -wpływ niedokorygowania. Podnosi się też możliwy hamujący wpływ na progresję tej wady refrakcji czasu spędzanego na zewnątrz pomieszczeń, czyli na świeżym powietrzu. Aby osiągnąć sukces w kontroli krótkowzroczności, należy wcześnie wykryć wadę, skorygować ją w pełni i zastosować najbardziej skuteczne metody zahamowania jej progresji.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Interventions to slow progression of myopia in children

Walline

Lindsley

Vedula

et al. 2011

Cochrane Database of Systematic Reviews

219

132

View full text Add to dashboard Cite

show abstract

“…11,12 Clearly, myopia has become an important public health issue, evidenced by the fact that it is one of the five ocular conditions listed as immediate priorities by the World Health Organization’s Global Initiative for the Elimination of Avoidable Blindness. 13 …”

mentioning

confidence: 99%

Myopia Progression Rates in Urban Children Wearing Single-Vision Spectacles

Donovan

Sankaridurg²,

et al. 2012

Optometry and Vision Science

168

154

View full text Add to dashboard Cite

Purpose To conduct a meta-analysis on the rates of myopia progression in urban children of Asian and predominately European ethnicities who are corrected with traditional single-vision spectacles. Methods A search of the National Library of Medicine’s PubMed literature database for articles on myopia progression was conducted using the terms ‘myopi*progression’ and MeSH terms ‘myopia’ and ‘disease progression’, and limited to publications from January 1990 and only for papers reporting data for humans < 16 years of age. Studies were excluded if they were non-randomized, did not use cycloplegic autorefraction, had a sample size less than 30 individuals, examined high myopia (worse than −6.0D) or special subject groups, presented myopia as part of a syndrome or condition, were retrospective, or used controls wearing optical corrections other than spectacles. Results Of 175 articles identified, 20 remained after applying the exclusion criteria. The estimated myopia progression at a mean age of 9.3 years after one year of follow-up was −0.55 D (95% C.I. −0.39 to −0.72 D) for populations of predominantly European extraction and −0.82 D (95% C.I. −0.71 to −0.93 D) for Asians. The estimated progression rates were dependent on baseline age, with decreasing progression as age increased. The rates also varied with gender. For an average baseline age of 8.8 years, estimated annual progression (combined ethnicities) was −0.80 D/year for females (95% CI: −0.51 to −1.10), and a significantly slower (p<0.01) −0.71 D/year for males (95% CI: −0.42 to −1.00). Conclusions In children wearing single-vision spectacles, higher myopia progression rates were found in urban Asians compared to urban populations of predominantly European descent. Younger children and females demonstrated greater annual rates of progression of myopia.

show abstract

“…Although anticataract agents are available all over the world [1], there are still no agents that have had their efficacy confirmed through reliable evaluation. On the other hand, the treatment of progressed cataract affecting vision has been almost perfectly established by the recent remarkable improvements of intraocular lens (IOL) surgery, an advancement of high importance to cataract patients and ophthalmologists in industrialized countries today.…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, the treatment of progressed cataract affecting vision has been almost perfectly established by the recent remarkable improvements of intraocular lens (IOL) surgery, an advancement of high importance to cataract patients and ophthalmologists in industrialized countries today. However, it is also true that the majority of people with blindness due to cataract in developing countries cannot be rescued by surgery alone, because of the situation of the economy in each country or lack of manpower in health services [1]. The numbers of IOL surgeries are continuously increasing, which has led to serious medicoeconomic problems in industrialized countries.…”

Section: Introductionmentioning

confidence: 99%

High Hurdle of Clinical Trials to Demonstrate Efficacy of Anticataractogenic Drugs

Sasaki

Hockwin²,

Sakamoto³

et al. 2000

Ophthalmologica

View full text Add to dashboard Cite

Recently, the rapid progression of cataract surgical technique has led cataract patients in industrialized countries to ignore the possibilities of drug therapy. Globally, however, it will be impossible in the near future to treat cataract by surgery alone, mainly due to medicoeconomic reasons. Preventative measures must be sought. As one of the these measures, the development of anticataractogenic drugs has reemerged as a focus in the lens research field. Although clinical trials of newly developed drugs are absolutely necessary before they enter the market, they have been considered to be a rather easy task. However, in order to gain accurate and reproducible data from trials, the trial program must be carefully prepared. The numbers of participants to the trial, the selection criteria of the subjects, the objective judgment of cataractous changes, follow-up period, a high technical level for cataract documentation and image analysis are proposed. Although there still remain some difficulties concerning the methods for objective judgment, a scientifically acceptable examination must be conducted.

show abstract

Editorial

Cited by 128 publications

References 0 publications

Interventions to slow progression of myopia in children

Interventions to slow progression of myopia in children

Myopia Progression Rates in Urban Children Wearing Single-Vision Spectacles

High Hurdle of Clinical Trials to Demonstrate Efficacy of Anticataractogenic Drugs

Contact Info

Product

Resources

About